Cefdinir

Cefdinir
Clinical data
Pronunciation	SEF-di-nir
Trade names	Cefzon, Omnicef, others
AHFS/Drugs.com	Monograph
MedlinePlus	a698001
License data	US DailyMed: Cefdinir;
Routes of; administration	By mouth
ATC code	J01DD15 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	16% to 21% (dose-dependent)
Protein binding	60% to 70%
Metabolism	Negligible
Elimination half-life	1.7 ± 0.6 hours
Excretion	Kidney
Identifiers
	IUPAC name 8-[2-(2-amino-1,3-thiazol-4-yl)-1-hydroxy-2-nitroso-; ethenyl]amino-4-ethenyl-7-oxo-2-thia-6-; azabicyclo[4.2.0]oct-4-ene-5-carboxylic acid;
CAS Number	91832-40-5 ;
PubChem CID	6915944;
DrugBank	DB00535 ;
ChemSpider	5291705 ;
UNII	CI0FAO63WC;
KEGG	D00917 ;
ChEBI	CHEBI:3485 ;
ChEMBL	ChEMBL927 ;
CompTox Dashboard (EPA)	DTXSID8046084 ;
ECHA InfoCard	100.171.145
Chemical and physical data
Formula	C14H13N5O5S2
Molar mass	395.41 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	170 °C (338 °F) (dec.)
	SMILES O=C2N1/C(=C(/C=C)CS[C@@H]1[C@@H]2NC(=O)C(=N\O)/c3nc(sc3)N)C(=O)O;
	InChI InChI=1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1 ; Key:RTXOFQZKPXMALH-GHXIOONMSA-N ;
	(verify)

Cefdinir, sold under the brand name Omnicef among others, is an antibiotic used to treat bacterial infections including bacterial pneumonia, other respiratory tract infections, otitis media, strep throat, and cellulitis. It may also be used as an alternative antibiotic for those with a severe penicillin allergy. It is taken by mouth.

Common side effects include diarrhea, nausea, and a skin rash. Serious side effects may include Clostridioides difficile infection, anaphylaxis, and Stevens–Johnson syndrome. Use in pregnancy and breastfeeding is believed to be safe but has not been well studied.

It is a third-generation cephalosporin antibiotic and works by interfering with a bacteria's ability to make a cell wall, resulting in its death.